Scarica l'app Stockscreener
161.87
0.22%
-0.35
Dopo l'orario di chiusura:
161.79
-0.08
-0.05%
Precedente Chiudi:
$162.22
Aprire:
$163.44
Volume 24 ore:
704.26K
Relative Volume:
0.73
Capitalizzazione di mercato:
$8.48B
Reddito:
$708.24M
Utile/perdita netta:
$-188.30M
Rapporto P/E:
-43.29
EPS:
-3.7392
Flusso di cassa netto:
$-70.99M
1 W Prestazione:
-4.83%
1M Prestazione:
-20.68%
6M Prestazione:
-12.11%
1 anno Prestazione:
+24.92%
Intervallo 1D:
$160.27
$169.96
Intervallo di 1 settimana:
$155.18
$170.80
Portata 52W:
$120.12
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
161.87 | 8.48B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-23 | Ripresa | Truist | Buy |
| 2026-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Why Axsome Therapeutics shares are falling today - Quiver Quantitative
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X - TradingView
Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% - Trefis
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - Yahoo Finance
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Motley Fool
Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities - The Globe and Mail
Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss - Trefis
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis
Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk - Moomoo
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada - MarketBeat
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 - GlobeNewswire
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting - Lelezard
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - tradingview.com
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - tradingview.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics Announces Results of the Shared Goals - globenewswire.com
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
| Mark Jacobson | Officer |
Sep 03 '26 |
Proposed Sale |
208.35 |
10,000 |
2,083,500 |
0 |
| Herriot Tabuteau | Officer |
Aug 06 '26 |
Proposed Sale |
210.13 |
4,660 |
979,206 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Sale |
213.95 |
4,660 |
997,007 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
4.95 |
4,660 |
23,067 |
11,889 |
| Herriot Tabuteau | Officer |
Aug 05 '26 |
Proposed Sale |
212.85 |
45,004 |
9,579,101 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Option Exercise |
4.95 |
45,004 |
222,770 |
52,233 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Sale |
212.01 |
45,004 |
9,541,298 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Sale |
240.25 |
49,666 |
11,932,256 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
4.95 |
49,666 |
245,847 |
56,895 |
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):